RANKL levels showed an increase in OM patients, though not statistically significant, aligning with recent evidences that RANKL alone is not a reliable marker to monitor bone destruction in a mouse model of osteomyelitis [38], as confirmed by a low AUC ROC. This evidence concerns the gene TNFSF11 and osteomyelitis.